Cell-Penetrating Peptide Nanofibers Boost Lung Drug Delivery by Up to 10-Fold | Research

The takeaway

Coating PLGA nanoparticles with self-assembling cell-penetrating peptide nanofibers increased drug delivery into lung cells by up to 10-fold and survived freeze-drying and nebulization for inhaled therapy.

10-fold increase
Supramolecular peptide nanofiber coating boosted nanoparticle delivery into endothelial cells 10-fold and into lung cells 3-fold, while surviving freeze-drying and nebulization for inhaled formulation

What the researchers found

The peptide nanofiber-coated PLGA nanocomposites demonstrated dramatically enhanced cellular uptake: 3-fold higher delivery into primary lung epithelial cells and macrophages, and 10-fold higher delivery into endothelial cells compared to naked PLGA nanoparticles. Compared to nanoparticles modified with traditional monomeric cell-penetrating peptides, the nanofiber-coated version still showed 2-fold improvement.

Mechanistic studies indicated that the nanocomposites enter cells through mixed macropinocytosis and passive energy-independent mechanisms, with endosomal escape occurring within 24 hours. The composites also demonstrated potent mucus permeation. The formulation survived freeze-drying and nebulization without losing physicochemical or biological activity, supporting translational potential as an inhaled therapeutic system.

Why it matters

Pulmonary drug delivery is one of the most important frontiers in medicine — from treating asthma and COPD to delivering gene therapies for cystic fibrosis and mRNA therapeutics for respiratory infections. Current nanoparticle systems are limited by poor mucus penetration and cellular uptake. By leveraging the self-assembling properties of cell-penetrating peptides to create a nanofiber coating, this approach provides a significant upgrade to standard PLGA nanoparticles with proven translational characteristics.

How the study worked

Supramolecular cell-penetrating peptides (CPPs) that self-assemble into nanofibers were coated onto PLGA nanoparticles to create nanocomposites. Cellular uptake was quantified in primary lung epithelial cells, macrophages, and endothelial cells and compared to naked PLGA and monomeric CPP-modified nanoparticles. Cell entry mechanisms were investigated through inhibitor studies. Mucus permeation was assessed. The formulation was tested for stability after freeze-drying and nebulization.

What this study cannot tell us

All studies are in vitro — no animal inhalation studies or in vivo pulmonary delivery data are presented. The 10-fold enhancement was in endothelial cells, while lung epithelial cells showed a more modest 3-fold improvement. The specific cell-penetrating peptide sequences used are not detailed in the abstract. Long-term stability of the freeze-dried formulation and potential immunogenicity of the peptide nanofibers in the lungs are not addressed. The drug payload capacity and release kinetics with actual therapeutic cargo are not characterized.

How to read the evidence

Published in ACS Applied Materials & Interfaces, this is a rigorous materials science study with thorough in vitro characterization including multiple cell types, mechanistic studies, mucus permeation, and formulation stability testing. However, all evidence is in vitro, and in vivo pulmonary delivery has not been demonstrated.

When this study was published

Published in 2022, this study reflects current advances in peptide-based drug delivery nanotechnology. The field continues to evolve rapidly with increasing focus on inhaled therapeutics.

The bigger picture

The intersection of peptide nanotechnology and pulmonary drug delivery is an active area of innovation. This work demonstrates that self-assembling peptide nanofibers can dramatically outperform individual cell-penetrating peptides — the supramolecular organization creates a multivalent surface that enhances cell interactions. As inhaled therapeutics gain importance (especially after COVID-19 highlighted pulmonary drug delivery), this nanocomposite platform could become a versatile tool for delivering nucleic acids, proteins, and small molecules to the lungs.

Questions still open

How do these nanocomposites perform in animal inhalation models — do the enhanced in vitro uptake numbers translate to improved drug delivery in vivo?
What is the immunogenicity profile of peptide nanofiber-coated nanoparticles when repeatedly inhaled into the lungs?
Can this platform effectively deliver mRNA, siRNA, or CRISPR components for gene therapy applications in pulmonary diseases?

Common questions

What are cell-penetrating peptides and why make them into nanofibers?

Cell-penetrating peptides (CPPs) are short amino acid sequences that can cross cell membranes, carrying attached cargo inside. When these peptides self-assemble into nanofibers and coat a nanoparticle, they create a dense, multivalent surface that is much more effective at entering cells than individual CPP molecules — in this case, up to 10 times better.

Could this be used as an inhaler for lung diseases?

That's the goal. The researchers showed the nanocomposites can be freeze-dried into a powder and then nebulized (turned into an inhalable mist) without losing their cell-penetrating abilities. This means they could potentially be formulated as an inhaled medicine for treating lung diseases like infections, asthma, COPD, or even for delivering gene therapies to the lungs.

Read the original research

Supramolecular Peptide Nanofiber/PLGA Nanocomposites for Enhancing Pulmonary Drug Delivery.

ACS applied materials & interfaces, 14(51), 56498-56509

View on PubMed ↗Publisher’s paper ↗

Citation

Chintapula, Uday; Yang, Su; Nguyen, Trinh; Li, Yang; Jaworski, Justyn; Dong, He; Nguyen, Kytai T. (2022). Supramolecular Peptide Nanofiber/PLGA Nanocomposites for Enhancing Pulmonary Drug Delivery.. ACS applied materials & interfaces, 14(51), 56498-56509. https://doi.org/10.1021/acsami.2c15204